Szent-Györgyi Prize: More Than a Nod to Mesothelioma Research

The fight against cancer is often characterized by incremental progress, by years of painstaking research yielding small but significant advances. Occasionally, however, a breakthrough emerges that doesn't just push the boundaries of knowledge but fundamentally reshapes our approach to a disease. We believe the recent award of the 2026 Szent-Györgyi Prize to Professor Michele Carbone for his pivotal work on mesothelioma is precisely one such moment.

Professor Carbone, from the University of Hawaii Cancer Center, was formally honored on October 9, 2026, in Washington, D.C., at the National Foundation for Cancer Research (NFCR) Global Summit. This prestigious recognition celebrates his groundbreaking discovery that susceptibility to mesothelioma, a rare and aggressive cancer of the lining of the lungs and abdomen, can be transmitted through families via inherited mutations in the BAP1 gene. This finding has profoundly transformed how the disease is understood, diagnosed, treated, and prevented worldwide, driving historic public policy changes that have saved lives across generations, as reported by the National Foundation for Cancer Research.

Unraveling Mesothelioma's Genetic Blueprint

Professor Carbone's seminal work began with a mystery. For over a decade, he immersed himself in remote villages in Cappadocia, Turkey, where residents were heavily exposed to erionite, a carcinogenic mineral fiber. In these communities, where up to half of all residents tragically died of mesothelioma, Carbone demonstrated that genetic predisposition, rather than environmental exposure alone, determined who developed the disease. This was a significant challenge to the prevailing dogma at the time that attributed the cause solely to environmental factors, as highlighted by NFCR's announcement and other sources.

His meticulous research led to the identification of germline BAP1 mutations as the cause of a novel cancer syndrome. This syndrome is characterized not only by mesothelioma but also by an increased risk for eye and skin melanoma, as well as renal, breast, and bladder cancers. The subsequent elucidation of the molecular mechanisms of BAP1 tumor suppressor activity has fundamentally reshaped the entire field of mesothelioma research, providing clarity to a long-standing medical mystery and offering hope to patients and families who previously had none.

Transforming Public Health and Clinical Practice

The impact of Carbone's discoveries extends far beyond scientific understanding; it has driven transformative public health action and reshaped clinical practice globally. In Cappadocia, Turkey, his research prompted the government to construct two entirely new villages and hospitals, relocating genetically susceptible populations away from carcinogenic erionite fibers. Similarly, in North Dakota, his work led the state government to repave more than 300 miles of erionite-contaminated roads, protecting children who had been exposed through dust raised by traffic, according to the University of Hawaii Cancer Center.

Today, BAP1 genetic testing and immunohistochemical staining are standard practices in medicine worldwide. These tools enable clinicians to identify patients with the BAP1 cancer syndrome and implement personalized surveillance, early detection, and effective intervention. The results are dramatic: patients with germline BAP1 mutations who are monitored and treated early survive significantly longer—with several living to old age—compared to those with sporadic mesothelioma, a disease that typically has a median survival of 6 to 18 months when caused by asbestos. Furthermore, the U.S. National Cancer Institute has opened two clinical trials directly in response to Carbone's discoveries, validating his findings and opening new avenues for treatment.

A Legacy of Courage and Compassion

The Szent-Györgyi Prize committee members lauded Professor Carbone's work for its profound human impact. Dr. Tony Hunter, Chair of the 2026 Prize Committee, described it as "a remarkable story of scientific courage and human compassion," noting how Carbone "took on a rare and neglected cancer, spent years in remote villages earning the trust of families, discovered the genetic basis of a disease that had claimed generations of lives, and then used that science to change government policy on two continents." Dr. Bruce Beutler, a Nobel Laureate, further emphasized that Carbone "broke open the entire field of mesothelioma pathogenesis." This sentiment was echoed by NFCR President and CEO Dr. Sujuan Ba, who stated that Carbone's career "exemplifies everything this prize stands for: a seminal discovery that opened a new field, and the persistence to translate that discovery into direct benefit for patients and communities around the world."

For Carbone himself, the reward is deeply personal. As he shared, "There is nothing as rewarding as saving lives, telling someone, actually you, your daughter, your son, do not have to die of cancer, you probably will live till old age, and then to see them again, year after year, happy." His journey, marked by scientific rigor and extraordinary dedication, serves as a powerful reminder of how curiosity, empathy, and persistent research can fundamentally alter the course of human health and inspire monumental change globally.